The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was 60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hypertrophy (13%), and baseline LVEF <50% (12%). Based on the intent to treat analysis, overall response rate was 72%, including 28 patients in complete remission (complete remission rate, 56%), and 8 in partial remission (16%). At the end of treatment, grades 3 to 4 cardiac events were observed in 6 patients. No significant modifications from baseline values of LVEF were observed during treatment and follow-up. Nonpegylated liposomal doxorubicin instead of doxorubicin in the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen is a feasible option for patients with diffuse large B-cell lymphoma presenting with concomitant cardiac disorders.

Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi / Luminari, Stefano; Viel, Elda; Ferreri, Andrés José Maria; Zaja, Francesco; Chimienti, Emanuela; Musuraca, Gerardo; Tucci, Alessandra; Balzarotti, Monica; Tani, Monica; Salvi, Francesca; Pesce, Emanuela A; Ferrari, Angela; Liberati, Anna M; Spadea, Antonio; Marino, Dario; Bruno-Ventre, Maria; Volpetti, Stefano; Bottelli, Chiara; Ravaioli, Elena; Merli, Francesco; Spina, Michele. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - (2018), pp. 1-8. [10.1002/hon.2425]

Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi

Luminari, Stefano
Writing – Original Draft Preparation
;
Pesce, Emanuela A
Formal Analysis
;
2018

Abstract

The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was 60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hypertrophy (13%), and baseline LVEF <50% (12%). Based on the intent to treat analysis, overall response rate was 72%, including 28 patients in complete remission (complete remission rate, 56%), and 8 in partial remission (16%). At the end of treatment, grades 3 to 4 cardiac events were observed in 6 patients. No significant modifications from baseline values of LVEF were observed during treatment and follow-up. Nonpegylated liposomal doxorubicin instead of doxorubicin in the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen is a feasible option for patients with diffuse large B-cell lymphoma presenting with concomitant cardiac disorders.
19-mag-2017
1
8
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi / Luminari, Stefano; Viel, Elda; Ferreri, Andrés José Maria; Zaja, Francesco; Chimienti, Emanuela; Musuraca, Gerardo; Tucci, Alessandra; Balzarotti, Monica; Tani, Monica; Salvi, Francesca; Pesce, Emanuela A; Ferrari, Angela; Liberati, Anna M; Spadea, Antonio; Marino, Dario; Bruno-Ventre, Maria; Volpetti, Stefano; Bottelli, Chiara; Ravaioli, Elena; Merli, Francesco; Spina, Michele. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - (2018), pp. 1-8. [10.1002/hon.2425]
Luminari, Stefano; Viel, Elda; Ferreri, Andrés José Maria; Zaja, Francesco; Chimienti, Emanuela; Musuraca, Gerardo; Tucci, Alessandra; Balzarotti, Monica; Tani, Monica; Salvi, Francesca; Pesce, Emanuela A; Ferrari, Angela; Liberati, Anna M; Spadea, Antonio; Marino, Dario; Bruno-Ventre, Maria; Volpetti, Stefano; Bottelli, Chiara; Ravaioli, Elena; Merli, Francesco; Spina, Michele
File in questo prodotto:
File Dimensione Formato  
luminari2017.pdf

embargo fino al 01/11/2018

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 154.34 kB
Formato Adobe PDF
154.34 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1152782
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 20
social impact